Nebenwirkungen · Docetaxel Kabi
DOCETAXEL KABI 160 mg/8 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 153–154
HOS-214897 · Präparat HOS-155350
153 MedDRA system organ Very common adverse Common adverse reactions classes reactions Infections and infestations Infections (G3/4: 5%) Blood and lymphatic system Neutropenia (G4: 54.2%); Febrile neutropenia disorders Anaemia (G3/4: 10.8%); Thrombocytopenia (G4: 1.7%) Immune system disorders Hypersensitivity (no severe) Metabolism and nutrition Anorexia disorders Nervous system disorders Peripheral sensory neuropathy Peripheral motor neuropathy (G3/4: 0.8%) (G3/4: 2.5%) Cardiac disorders Arrhythmia (no severe) Vascular disorders Hypotension Gastrointestinal disorders Nausea (G3/4: 3.3%); Constipation Stomatitis (G3/4: 1.7%); Vomiting (G3/4: 0.8%); Diarrhoea (G3/4: 1.7%) Skin and subcutaneous tissue Alopecia; Nail disorders (severe: 0.8%) disorders Skin reaction (G3/4: 0.8%) Musculoskeletal and Myalgia connective tissue disorders General disorders and Asthenia (severe: 12.4%); administration site conditions Fluid retention (severe: 0.8%);Pain Investigations G3/4 Blood bilirubin increased (< 2%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 00521e80e895cd86d47a313dfa25f3cf4c2acb1848ffaafc32416e3d3031fa2c · Zeichen 10369–12078 im Abschnitt